MDM2 and cutaneous melanoma: Early studies proposed that the combination of dabrafenib and trametinib improved anti-tumor activity and survival in BRAF mutant melanoma patients [26], and follow-up research reported that trametinib induced the reduction of DUSP6, while the result of increased p53 phosphorylation synergizes with MDM2 inhibition in cutaneous melanoma [27].